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There is accumulating evidence of the neurological and neuropsychiatric features of infection with SARS-CoV-2. 
In this systematic review and meta-analysis, we aimed to describe the characteristics of the early literature and 
estimate point prevalences for neurological and neuropsychiatric manifestations. 
 
Methods 
We searched MEDLINE, Embase, PsycInfo and CINAHL up to 18 July 2020 for randomised controlled trials, 
cohort studies, case-control studies, cross-sectional studies and case series. Studies reporting prevalences of 
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13,292 records were screened by at least two authors to identify 215 included studies, of which there were 37 
cohort studies, 15 case-control studies, 80 cross-sectional studies and 83 case series from 30 countries. 147 studies 
were included in the meta-analysis. The symptoms with the highest prevalence were anosmia (43.1% [35.2—51.3], 
n=15,975, 63 studies), weakness (40.0% [27.9—53.5], n=221, 3 studies), fatigue (37.8% [31.6—44.4], n=21,101, 67 
studies), dysgeusia (37.2% [30.0—45.3], n=13,686, 52 studies), myalgia (25.1% [19.8—31.3], n=66.268, 76 studies), 
depression (23.0 % [11.8—40.2], n=43,128, 10 studies), headache (20.7% [95% CI 16.1—26.1], n=64,613, 84 
studies), anxiety (15.9% [5.6—37.7], n=42,566, 9 studies) and altered mental status (8.2% [4.4—14.8], n=49,326, 19 
studies). Heterogeneity for most clinical manifestations was high. 
 
Conclusions 
Neurological and neuropsychiatric symptoms of COVID-19 in the pandemic’s early phase are varied and common. 
The neurological and psychiatric academic communities should develop systems to facilitate high-quality 
methodologies, including more rapid examination of the longitudinal course of neuropsychiatric complications of 
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INTRODUCTION 
COVID-19 stimulated a global academic response to examine the clinical sequelae and biology of the SARS-CoV-2 
virus, including its neurological and neuropsychiatric impact. [1,2] Although the earliest reports naturally 
highlighted respiratory symptoms, [1] it was quickly recognised that SARS-CoV-2, like other coronaviruses, [2] can 
affect the central and peripheral nervous system. [3,4]  
 
Many of the very earliest studies of the neurological and neuropsychiatric complications of SARS-CoV-2 infection 
were small retrospective case reports or series. [7,8] These initial studies were feasible to deliver quickly in the 
context of a new and poorly understood disease. Case reports [5,6] were superseded by case series [7,8], then case-
control [9] and cohort studies [10,11], which suggested significant morbidity and mortality from neurological or 
neuropsychiatric complications. [12]  Currently, large multi-centre prospective studies are underway [13] and 
already reporting. [14] We anticipate that the quality of evidence, and our knowledge, will improve considerably 
as these data continue to emerge rapidly.  
 
In response to these signals, we aimed to develop a novel, sustainable platform to evaluate emerging knowledge of 
the neurology and neuropsychiatry of COVID-19. This also served to assist colleagues in keeping up to date with 
the literature relevant to their specialty, given the extraordinary volume and pace with which research is being 
published. In May 2020 we started logging literature on relevant symptoms, clinical associations, and putative 
underlying mechanisms in our blog, “The neurology and neuropsychiatry of COVID-19”, published weekly on the 
Journal of Neurology, Neurosurgery and Psychiatry website. [15] This catalogue of observational studies, reviews, 
editorials, and mechanistic studies has had over 27,000 global views, but it is essentially a library in which studies 
are narratively summarised and filed. We recognised the potential value of extending this platform to enable 
analytic summaries by synthesising evidence in the form of a systematic review and meta-analysis, which we 
termed Systematically Analyse and Review Studies of COVID-19 Neurology and neuropsychiatry (SARS-COV-
Neuro). 
 
In the current report we aimed to answer two questions: 
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1. What were the key methodological characteristics of the early evolving literature on the neurological and 
neuropsychiatric consequences of COVID-19? 
2. What was the prevalence of neurological and neuropsychiatric complications in COVID-19 patients in 
observational or interventional studies during this early period of evolving knowledge?  
 
This review is the most comprehensive attempt yet to synthesise the data on the neurological and neuropsychiatric 
consequences of COVID-19. Other previous works are less up-to-date, incorporate fewer clinical parameters or 
have limited scope for meta-analysis. [2,16–19] 
 
METHODS 
We conducted a systematic review and meta-analysis, based on a registered protocol (PROSPERO ID 
CRD42020200768) and reported according to PRISMA guidelines [20] (see Supplementary Table 1 for completed 
PRISMA checklist).  
 
The overall strategy was to combine synonyms for COVID-19 infection with synonyms for neurological and 
neuropsychiatric syndromes. We searched Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-
Indexed Citations and Daily, EMBASE (via Ovid), APA PsycInfo (via OVID) and CINAHL (via EBSCO) from 1st 
January 2020 to 18th July 2020. Reference lists of other systematic reviews were examined and cross-checked 
against our database and eligibility criteria. The full search strategy is presented in Supplementary methods 1. 
 
We included any controlled trials, cross-sectional, case-control, cohort studies or case series reporting 
neuropsychiatric or neurological manifestations in confirmed or clinically suspected COVID-19 patients. We 
excluded non-English language reports.  We excluded studies reporting on fewer than 10 infected patients to avoid 
the reporting biases common in small studies. Meta-analysis was conducted where a clinical manifestation was 
reported by three or more eligible studies. Studies were included in the meta-analysis only where they provided 
representative samples of patients with COVID-19 in whom the point prevalence of neurological or 
neuropsychiatric features could be estimated; studies where patient inclusion was based on neurological or 
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neuropsychiatric complications (e.g. only those referred for clinical neuroimaging) were therefore excluded from 
the meta-analysis. 
 
Screening of titles, abstracts and full texts for each article was conducted by two of the authors (CW, JS, AGR, BC, 
MB, DH, JB, ER), each blinded to the other’s ratings. Where there was disagreement about study inclusion, a third 
author who was a senior member of the team (AGR, MB, JS or JPR) arbitrated. Zotero was used for reference 
management and Rayyan QCRI was used for eligibility screening.  
 
Data extraction was performed on structured forms by two authors: one of the authors (ER, DH, BC, CW, HM, JB) 
entered the data, then a second author (AGR, MB, CH, AS, JB, JS, BC, ER, HM, DA, SR or MFL) ensured the 
accuracy of each data item by cross-checking against the original source. We recorded the methodological 
characteristics of studies and the frequency of neurological and neuropsychiatric manifestations reported by each 
study (see full list of variables extracted in Supplementary table 2). Where data were available for an outcome at 
follow-up rather than during the acute illness, prevalences at follow-up were presented separately. Where studies 
reported asthenia as a manifestation, this was coded as fatigue; where a paper reported both asthenia and fatigue, 
only the figures for fatigue were used. 
 
Levels of evidence were assessed by use of the Oxford Centre for Evidence-based Medicine Levels of Evidence. [21] 
Quality of studies and risk of bias were assessed using the Newcastle-Ottawa Scale, including its adaptation for 
cross-sectional studies. [22,23] Quality was assessed by two authors in parallel with arbitration by a third author in 
cases of disagreement. 
 
For the systematic review, we descriptively reported methodological characteristics of the evolving literature with 
analytic statistical tests where appropriate. All eligible studies were listed in a table with their study design, 
demographics and main findings. 
 
For the meta-analysis, the primary outcome was point prevalence of neurological and neuropsychiatric 
manifestations with 95% confidence intervals. Given the potential for estimation errors with a double-arcsine 
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transformation of proportion, [24] we used the metafor package in R version 4.0.2 to calculate generalised linear 
mixed models (GLMMs) for each outcome, [25,26] before then using the double arcsine transformation as a 
comparative sensitivity analysis. [27,28] Outcome proportions were transformed using a logit transformation. 
Between-study heterogeneity was calculated using the I2 statistic. We planned a priori to analyse the following 
subgroups: retrospective or prospective design, method of SARS-CoV-2 diagnosis, severity of COVID-19, and time-
point in relation to infection. Ultimately, we only conducted subgroup analysis for retrospective or prospective 
design and severity of COVID-19 because of lack of consistently presented data for the other subgroups. In addition, 
due to high heterogeneity, we conducted an additional exploratory subgroup analysis examining country of origin. 
Subgroup analyses were conducted on the five clinical manifestations most commonly studied: anosmia, dysgeusia, 




De-duplicated searches returned a total of 13,292 titles. Abstract and full text screening generated a final list of 215 
eligible studies (Figure 1). A complete list of all included studies is presented in Supplementary Table 3. 
 
Methodological characteristics of the literature 
Methodological characteristics of the studies are summarised in Table 1. The most common study type was a case 
series (83 studies, 38.6%). To explore whether designs evolved in the first half of 2020, we considered studies that 
started data collection in December 2019 to February 2020 to be earlier and those between March and July 2020 to 
be later. Among the earlier studies, 37 out of 65 (57%) were case series, whereas this proportion fell to 40 out of 
115 (34.8%) among the subsequent studies, p=0.004. Change in study design is illustrated in Figure 2. Overall, 
therefore, there was at least a two-month lag period from the first official report of the outbreak in Wuhan by the 
Chinese authorities (31st Dec 2019) to the first group of cohort studies. 
 
Studies were written by a primary author affiliated with an institution from a total of 30 countries globally (Figure 
3). The most frequent contributors were China (n=50 studies), USA (n=32 studies), Italy (n=28 studies), and France 
(n=23 studies).  All but three studies starting recruitment in Jan 2020 were located in China. Globally, most studies 
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(138, 64.2%) were single-centre without a significant shift towards multi-centre studies as the pandemic 
accelerated: where collection date was clear, 44/65 (67.7%) of earlier studies were single-centre, compared to 
72/115 (62.6%) of later studies (p=0.49).  
 
Studies were predominantly in hospitalised patients (118 studies, 54.9%) and during the acute illness (144, 67.0%). 
There were a total of 105,638 subjects. Number of subjects in each study varied between 10 and 40,469 (median 
101, IQR 196). There were 18 studies with 1000 or more subjects.  
 
There was evidence for ethical approval and informed consent in most studies, but this was waived in a minority, 
frequently because of the particular circumstances of the pandemic.  
 
Quality assessment found only 23 (10.7%) studies to be of high quality, 98 (45.6%) were of moderate quality and 94 
(43.7%) were of low quality.  
 
Table 1: Methodological characteristics of included studies 






























OCEBM Level of Evidence 
- Random sampled study (Level 1) 
- Local, non random sample (Level 3) 
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- Outpatients 
- Emergency department attendances 
- Mixed treatment settings 











- Other laboratory technique 
- Radiology 
- Clinical opinion 
- Mixed method 
















- Acute illness 
- After hospital discharge or recovery 
- Deceased 
- Mixed 

























Informed consent  
- Required 
- Waived 























Prevalence of neuropsychiatric and neurological manifestations 
Twenty neurological or neuropsychiatric manifestations were estimated by at least 3 studies, such that we included 
147 studies (reporting on 99,905 infected patients) in the meta-analysis. Overall prevalences are shown in Table 2 
with forest plots available in Figure 4 and Supplementary Figures 1-20. The most often-studied symptoms were 
headache (examined in 84 studies, n=64,613), myalgia (76 studies, n=66,268), fatigue (67 studies, n=21,101), 
anosmia (63 studies, 15,975) and dysgeusia (52 studies, n=13,686). The most prevalent symptoms were anosmia 
(43.1% [35.2-51.3], n=15,975 in 63 studies), weakness (40.0% [27.9-53.5], n=221 in 3 studies), fatigue (37.8% [31.6-
44.4], n=21,101 in 67 studies) dysgeusia (37.2% [29.8-45.3], n=13,686 in 52 studies) and myalgia (25.1% [19.8-31.3], 
n=66,268 in 76 studies). Sleep disorder was a broad term that was used in a number of studies; of the 8 studies 
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reporting a sleep problem, 2 specified insomnia, 1 sleep impairment and the remainder an unspecified sleep 
disorder. 
 
Between-study heterogeneity was mostly high with I2≥90% for 13 manifestations, ≥50% and <90% for 2 
manifestations and <50% for 5 manifestations. Most symptoms were recorded merely as ‘present’ or ‘absent’ by 
study authors. The robustness of the main analyses was assessed by repeating the analyses on headache, myalgia, 
anosmia, fatigue and dysgeusia using the standard random-effects model for meta-analysis with the Freeman-
Tukey double arcsine transformation. The results were in line with the main analysis (see Supplementary table 4). 
 
Table 2: Overall meta-analytic estimates of point prevalence of neurological or neuropsychiatric symptoms 
Symptom/Syndrome Studies  n Point 
prevalence 
(%) 
95% CI I2  
Headache 84 64,613 20.7 16.1 - 26.1 99.0% 
Myalgia 76 66,268 25.1 19.8-31.3 99.1% 
Fatigue 67 21,101 37.8 31.6 – 44.4 98.7% 
Anosmia 63 15,975 43.1 35.2 – 51.3 98.8% 
Dysgeusia  52 13,686 37.2 29.8 – 45.3  98.6% 
Dizziness/vertigo 26 47,619 6.4 4.0 - 10.0 97.1% 
Altered mental status  19 49,326 8.2 4.4 - 14.8 99.0% 
Anosmia at follow-up 11 3,182 11.8 5.5 – 23.5 98.5% 
Depression 10 43,128 23.0 11.8 - 40.2 99.3% 
Anxiety  9 42,566 15.9 5.6 - 37.7 99.5% 
Sleep disorder 8 42,221 23.5 12.0 - 40.9 98.9% 
Ischaemic stroke 8 5,258 1.9 1.3 – 2.8 61.7% 
Other CVD 6 43,701 1.6 0.3 – 7.9 98.7% 
Dysgeusia at follow-up 6 2,065 11.7 5.1– 25.0 96.7% 
Seizure 5 41,929 0.06 0.06 – 0.07 0.0% 
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Haemorrhagic stroke 5 3,074 0.4 0.3 - 0.7 0.0% 
Visual defect 5 678 3.0 1.9 - 4.5 0.0% 
Hearing impairment 4 557 2.0 1.1 – 3.5 0.0% 
Tinnitus  4 455 3.5 1.7 – 7.4 51.8% 
Weakness 3 221 40.0 27.9 – 53.5 45.4% 
 
Subgroup analyses:  
Subgroup analysis was conducted by study design (prospective and retrospective; Table 3), case severity 
(outpatient, mixed non-severe, non-severe inpatients, severe but not admitted to ITU  and admitted to ITU; Table 
4) and country of origin (Supplementary Table 5). For headache, myalgia, anosmia and dysgeusia, there were 
significantly higher reported rates in prospective studies than in retrospective studies. In the severity subgroup 
analysis, compared to the ITU group, headache was more common in mixed non-severe and outpatient populations 
(p<0.001); myalgia was more common in mixed non-severe and outpatient populations (p=0.04 and <0.001 
respectively); anosmia was more common in mixed non-severe and outpatient populations (p=0.05 and 0.04, 
respectively), and dysgeusia was more common in mixed non-severe populations (p=0.02); there were no 
significant differences between groups for fatigue. 
 
Table 3: Subgroup analysis by study design for 5 most commonly studied clinical manifestations 
Manifestation Retrospective Prospective p 
Studies Prevalence (95% CI) I2 Studies Prevalence (95% CI) I2 
Headache 46 11.1 
(8.0-15.3) 
98.3 34 37.5 (29.3-46.5) 98.2  <0.001 
Myalgia 42 16.8 (11.8-23.1) 99.1 30 38.6 (29.6-48.5) 98.5 <0.001 
Anosmia 16 22.3 (11.4-39.0) 98.0 44 50.8 
(42.5-59.1) 
98.6 <0.005 
Dysgeusia 13 22.3 (11.0-40.2) 97.8 36 42.4 (34.4-50.9) 98.5 0.04 
Fatigue 41 33.5 
(26.1-41.8) 
98.8 24 43.3 (33.2-54.1) 98.5 0.14 
 
 




Table 4: Subgroup analysis by case severity for 5 most commonly studied clinical manifestations 
Manifestat
ion 





























































































































































To our knowledge, this is the largest and most comprehensive systematic review of the neurological and 
neuropsychiatric manifestations of COVID-19. We identified 215 studies, published between January and July 
2020, with a total population of 105,638, containing a large variation in the size of studies. We uncovered some 
general findings about the methodological characteristics of early-evolving literature in response to a novel 
pathogen. Studies varied substantially in design, geographical location, treatment setting, illness stage, sample size, 
diagnostic method and clinical manifestations studied. More studies were retrospective than prospective and case 
series comprised a significant minority of the early literature. In terms of country of origin, after the first few 
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weeks of the pandemic in which the literature was dominated by studies from China, a wide range of research was 
produced from 30 countries, among which less economically developed countries were mostly absent. Most studies 
confirmed formal ethical review and most required informed consent, but these requirements were waived in a 
subset of cases.  
 
In our review we summarise point prevalence of 20 neurological and neuropsychiatric complications of COVID-
19. The most frequently studied symptoms were heavily weighted towards non-specific features of systemic illness, 
such as headache, myalgia, fatigue, anosmia and dysgeusia, which are unlikely to be ‘primary’ neurological 
symptoms. It was predominantly these more non-specific symptoms that were found to have the highest 
prevalences, ranging from 20.7% [16.1-26.1] to 43.1% [35.2-51.3] (headache and anosmia, respectively). Of note, 
more specific neurological and neuropsychiatric symptoms such as altered mental status, depression, anxiety, sleep 
disorder, stroke and seizures were less frequently studied. However, the core psychiatric disorders of depression 
(23.0% [11.8-40.2]) and anxiety (15.9% [5.6-37.7]) appeared to be highly prevalent. The reported prevalence of 
major neurological disorders such as ischaemic stroke (1.9% [1.3-2.8]), haemorrhagic stroke (0.4% [0.3-0.7%]) and 
seizure (0.06% [0.06-0.07]) were substantially lower. Subgroup analyses suggested that study design (prospective 
versus retrospective), severity of illness and country of origin of a study affected the prevalence figures obtained. 
Importantly, for myalgia, fatigue, anosmia and dysgeusia, prevalence rates were substantially higher in prospective 
studies compared to retrospective studies.  
 
There are several limitations to our study, relating both to the quality of the underlying evidence and to the data 
synthesis. Major limitations in the study design were the frequent absence of comparison groups, limiting 
conclusions about the specificity of symptoms to COVID-19; retrospective study designs, which meant that only 
those symptoms that happened to be enquired about were included; and small sample sizes, which risk reporting 
bias. In terms of populations, the frequent use of hospital inpatients is unrepresentative of the majority of patients 
with COVID-19, who are not admitted to hospital. Regarding clinical manifestations, the main limitations were 
reliance on self-report measures, which risks recall biases; lack of baseline assessment, which prevents estimation 
of incidence; and a focus on non-specific neuropsychiatric symptoms rather than on major neurological and 
neuropsychiatric disorders. In addition, some of the most commonly studied symptoms (such as weakness and 
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fatigue) have some conceptual overlap, [29] so it is possible that the prevalences found in this review may be 
underestimated. Terminology connoting altered mental status varied, with terms such as delirium and 
encephalopathy chosen in different studies, despite existing recommendation on standardisation of the 
nomenclature. [30] The finding that only 14.4% of the studies were of high quality limits the strength of any 
conclusions that can be drawn. In terms of the data synthesis, we were limited by excluding studies not published 
in English, which may particularly have reduced the number of important studies included from China, and the 
generalisability of our results may be limited by the geographical scope of the studies. The rapidly evolving 
literature means that any review on this subject risks becoming out of date. Furthermore, the high heterogeneity 
between studies, even after subgroup analyses, suggests that variation in populations, outcomes and measurement 
techniques might account for much of the differences between studies. Finally, the cross-sectional nature and the 
focus on acute presentations of most studies reported to-date limit our ability to draw conclusions about the long-
term impact of neuropsychiatric post-COVID-19 symptom burden. Future well-designed prospective cohorts, such 
as the UK-based Post-hospitalisation COVID-19 study (https://www.phosp.org/), may be able to address this gap in 
the knowledge. 
 
There are several implications of this review for future research. Firstly, while retrospective studies are important 
in identifying associations in large patient populations, they are likely to underestimate the prevalence of 
important symptoms. This may particularly be the case with some neuropsychiatric disorders such as depression 
and delirium, which are known to be generally under-recognised. [31,32] Therefore, even in the context of a 
pandemic, there is a need to improve the speed with which the academic community can produce prospectively 
designed studies, which are based on registered protocols and use validated and objective measures. Standardised 
case definitions and record forms for common neurological manifestations of viral infections were produced by the 
Brain Infections Global Network from early in the pandemic [33] and made freely available. These have been 
modified by other international groups, [34] and are being incorporated into the WHO case report forms. [35] 
More studies are required of those not admitted to hospital and the timing of neurological and neuropsychiatric 
symptoms relative to diagnosis must be specified. In terms of the clinical manifestations, many of the common and 
debilitating neurological symptoms (such as headache, myalgia and anosmia) were assessed systematically by a 
large number of studies, allowing for meaningful prevalence estimates and subgroup analyses. However, some 
 
  15 
severe neurological and neuropsychiatric disorders, such as depression, stroke and seizures, received comparatively 
scant attention and would benefit from similar study. Finally, the occasional waivers of ethical review and the 
more frequent waivers of informed consent in these studies illustrates that some aspects of study review may be 
overly burdensome - and therefore potentially neglected - during a pandemic. Whilst we acknowledge the need 
for proper ethical and institutional oversight, COVID-19 may be an opportunity for this process to be streamlined 
across the field, especially for non-interventional studies, where the risks to participants are minimal, so that 
studies during a pandemic (and beyond) can start quickly and inform urgent policy needs.  
 
There are several clinical implications of our study. Firstly, practitioners should be aware that neurological and 
neuropsychiatric symptoms are very common with four (anosmia, weakness, dysgeusia and fatigue) estimated to 
occur in more than 30% of patients. Secondly, these non-specific neurological and neuropsychiatric symptoms 
appear to be the most common. Neuropsychiatric disorders such as anxiety and depression occupy an intermediate 
space with prevalence of between 15.9% [5.6-37.7] and 23.0% [11.8-40.2]), while major neurological disorders such 
as stroke and seizures are much rarer. However, because of the very high number of individuals infected with 
SARS-CoV-2 worldwide, even less frequent symptoms may still result in a substantial increase in the burden of 
disease. This means that services for those with common mental illnesses and neurological rehabilitation should be 
resourced and equipped for an increase in case numbers. Many of these disorders can become chronic, so the 
neurological and psychiatric impact of the pandemic may substantially outlast the current phase. Thirdly, given 
the multitude of symptoms reported, neurological and neuropsychiatric comorbidity is likely to be the norm rather 
than the exception in COVID-19, so there must be accessible advice and input from these specialties for patients 
who are acutely unwell. Finally, although there is a relative lack of data on non-hospitalised patients, the data 
available suggest that several symptoms, such as anosmia, dysgeusia, fatigue, headache and myalgia, are common 
even among those with milder illness. Although long-term evidence from this earliest literature was sparse, it gives 
some initial indication that the symptoms described in ‘long COVID’ may be a continuation of some of those 
experienced in the acute phase of the illness. [36] Long COVID is, however, likely to be a heterogeneous entity 
with a multifactorial aetiology, including viral persistence, inflammatory changes, physical deconditioning and 
psychological factors. Our finding that the most frequently reported neurological symptoms actually occurred 
more frequently in those with less severe COVID-19 suggests that neurological symptoms are not necessarily 
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correlated with systemic or respiratory symptoms, implying that different mechanisms or timing of mechanisms 
may be involved. 
 
In conclusion, COVID-19 is accompanied by a wide range of neurological and neuropsychiatric symptoms from 
the common, such as fatigue and anosmia, to the more infrequent but severe, such as stroke and seizure. There is 
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Proportion of patients reporting dysguesia in SARS−CoV−2 infection by patient severity
Supplementary methods 1: Full search strategy 
Per phase one of our strategy and for the current manuscript we populated the database with a 
search extending from 1st Jan 2020 to 18th July 2020. Future phases will update the database 
on a progressively shortening basis. To enable this we will continuously run the processes 
described below. Successive iterations of the database will be version and date-controlled.  
 
Information sources 
We searched Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed 
Citations and Daily, EMBASE (via Ovid), APA PsycInfo (via OVID) and CINAHL (via EBSCO) 
from 1st Jan 2020 to 18th July 2020. Individualised search strategies for each database were 
deposited with CRD. Reference lists of systematic review articles were examined and cross-
checked against our database and eligibility criteria. We noted foreign language papers but did 
not translate these. 
 
Search Strategy  
MEDLINE  
(Coronavirus or corona virus or coronavirinae or coronaviridae or betacoronavirus or Covid19 or 
Covid 19 or Covid-19 or nCoV or CoV 2 or CoV2 or CoV-2 or Sarscov2 or SARS-CoV-2 or 
2019nCoV or novel CoV or Wuhan virus or ((Wuhan or Hubei or Huanan) and (respiratory or 
pneumonia or virus))).mp. or exp Coronavirus/ or exp Coronavirus Infections/ or 
Coronaviridae.mp. 
AND  
(neurol* or nervous or brain or CNS or encephal* or mening* or Cranial* or myeli* or demyeli* or 
ADEM or ataxi* or dysphasi* or aphasi* or stroke or guillain-barre or Miller-Fisher or paresis or 
palsy or cerebr* or crani* or epilep* or seizure or headache* or migraine* or dysgeusia or 
anosmia or taste or smell or psych* or neuropsych* or mania or manic or psycho* or delusion* 
or hallucin* or functional or catatoni* or cognit* or dement* or delir* or depress* or anxi* or 
obsess* or post-traum* or posttraum* or PTSD or behaviour or behavior or fatigue* or MRI or 
CT or neuroimag* or scan* or neurotrop* or neuroinvas* or neuropath* or cerebrospinal* or 
cerebro-spinal* or confus* or conscious* or letharg* or psychomotor* or psycho-motor* or 
agitat*).mp. or exp Neurology/ or exp Nervous System/ or exp Nervous System Diseases/ or 
exp Neurologic Manifestations/ or exp Psychiatry/ or exp Mental Disorders/ or exp Mental 
Processes/ or exp Behavioral Symptoms/ or exp Psychological Phenomena/ 
 
EMBASE  
(Coronavirus or corona virus or coronavirinae or coronaviridae or betacoronavirus or Covid19 or 
Covid 19 or Covid-19 or nCoV or CoV 2 or CoV2 or CoV-2 or Sarscov2 or SARS-CoV-2 or 
2019nCoV or novel CoV or Wuhan virus or ((Wuhan or Hubei or Huanan) and (respiratory or 
pneumonia or virus))).mp. or exp Coronavirinae/ or exp Coronavirus Infection/ or exp 
Coronaviridae/ or exp Coronaviridae infection/ or exp SARS Coronavirus/ 
AND 
(neurol* or nervous or brain or CNS or encephal* or mening* or Cranial* or myeli* or demyeli* or 
ADEM or ataxi* or dysphasi* or aphasi* or stroke or guillain-barre or Miller-Fisher or paresis or 
palsy or cerebr* or crani* or epilep* or seizure or headache* or migraine* or dysgeusia or 
anosmia or taste or smell or psych* or neuropsych* or mania or manic or psycho* or delusion* 
or hallucin* or functional or catatoni* or cognit* or dement* or delir* or depress* or anxi* or 
obsess* or post-traum* or posttraum* or PTSD or behaviour or behavior or fatigue* or MRI or 
CT or neuroimag* or scan* or neurotrop* or neuroinvas* or neuropath* or cerebrospinal* or 
cerebro-spinal* or confus* or conscious* or letharg* or psychomotor* or psycho-motor* or 
agitat*).mp. or exp Neuroscience/ or exp Nervous System/ or exp Neurologic Disease/ or exp 
Psychiatry/ or exp Mental Disease/ or exp Behavior/ or exp Mental Function/ or exp Confusion/ 
or exp Psychophysiology/ 
 
PsycINFO  
(Coronavirus or corona virus or coronavirinae or coronaviridae or betacoronavirus or Covid19 or 
Covid 19 or Covid-19 or nCoV or CoV 2 or CoV2 or CoV-2 or Sarscov2 or SARS-CoV-2 or 
2019nCoV or novel CoV or Wuhan virus or (Wuhan or Hubei or Huanan)).mp. 
AND  
(neurol* or nervous or brain or CNS or encephal* or mening* or Cranial* or myeli* or demyeli* or 
ADEM or ataxi* or dysphasi* or aphasi* or stroke or guillain-barre or Miller-Fisher or paresis or 
palsy or cerebr* or crani* or epilep* or seizure or headache* or migraine* or dysgeusia or 
anosmia or taste or smell or psych* or neuropsych* or mania or manic or psycho* or delusion* 
or hallucin* or functional or catatoni* or cognit* or dement* or delir* or depress* or anxi* or 
obsess* or post-traum* or posttraum* or PTSD or behaviour or behavior or fatigue* or MRI or 
CT or neuroimag* or scan* or neurotrop* or neuroinvas* or neuropath* or cerebrospinal* or 
cerebro-spinal* or confus* or conscious* or letharg* or psychomotor* or psycho-motor* or 
agitat*).mp OR exp Psychiatry/ OR exp Mental Disorders/ OR exp Sensory System Disorders/ 
OR exp Sense Organ Disorders/ OR exp Nervous System Disorders/ OR exp Neurosciences/ 
OR exp Neurocognitive Disorders or exp Emotional States 
 
CINAHL  
(Coronavirus or corona virus or coronavirinae or coronaviridae or betacoronavirus or Covid19 or 
Covid 19 or Covid-19 or nCoV or CoV 2 or CoV2 or CoV-2 or Sarscov2 or SARS-CoV-2 or 
2019nCoV or novel CoV or Wuhan virus or ((Wuhan or Hubei or Huanan) and (respiratory or 
pneumonia or virus))) OR (MH "Coronavirus+") OR (MH "Coronavirus Infections+") OR (MH 
"Coronaviridae+")   
AND 
( (neurol* or nervous or brain or CNS or encephal* or mening* or Cranial* or myeli* or demyeli* 
or ADEM or ataxi* or dysphasi* or aphasi* or stroke or guillain-barre or Miller-Fisher or paresis 
or palsy or cerebr* or crani* or epilep* or seizure or headache* or migraine* or dysgeusia or 
anosmia or taste or smell or psych* or neuropsych* or mania or manic or psycho* or delusion* 
or hallucin* or functional or catatoni* or cognit* or dement* or delir* or depress* or anxi* or 
obsess* or post-traum* or posttraum* or PTSD or behaviour or behavior or fatigue* or MRI or 
neuroimag* or scan* or neurotrop* or neuroinvas* or neuropath* or cerebrospinal* or cerebro-
spinal* or confus* or conscious* or letharg* or psychomotor* or psycho-motor* or agitat*) OR ) 
OR (MH "Neurology") OR (MH "Nervous System+") OR (MH "Nervous System Diseases+") OR 
(MH "Neurologic Manifestations+") OR (MH "Psychiatry+") OR (MH "Mental Processes+") OR 
(MH "Diagnosis, Neurologic+") OR ( (MH "Behavioral and Mental Disorders+") ) 
Supplementary Methods 2: Author contributions 
 
Author Contribution(s) 
All authors ● Made a substantial intellectual contribution to the study 
● Approved the final manuscript 
Dr Jonathan P 
Rogers 
● Led and coordinated final phase of study 
● Wrote manuscript 
● Conducted quality assessment 
● Sorted references 
● Calculated descriptive statistics 
● Consulted on study inclusion 
● Arbitrated with quality assessment 
● Checked completed manuscript 
Dr Cameron 
Watson 
● Conducted meta-analysis 
● Screened studies for eligibility 
● Extracted data 
Mr James 
Badenoch 
● Screened studies for eligibility 
● Extracted data 
● Checked data extraction 
● Conducted quality assessment 
● Checked adherence to PRISMA guidelines 
● Made PRISMA flowchart 
● Sorted references 
● Drafted limitations of study 
● Checked completed manuscript 
Dr Benjamin 
Cross 
● Screened studies for eligibility 
● Extracted data 
● Checked data extraction 
● Conducted quality assessment 
Dr Matthew 
Butler 
● Screened studies for eligibility 
● Consulted on screening studies 
● Checked data extraction 
● Conducted quality assessment 
● Compared to other systematic reviews 
● Drafted limitations of study 
● Checked citations 
● Checked completed manuscript 
Dr Jia Song  ● Screened studies for eligibility 
● Consulted on screening studies 
● Checked data extraction 
● Conducted quality assessment 
● Checked completed manuscript 
Mr Danish 
Hafeez 
● Screened studies for eligibility 
● Extracted data 
● Checked data extraction 
● Conducted quality assessment 
● Assisted in creating figure illustrating change in study design 
Dr Hamilton 
Morrin 
● Extracted data 
● Checked data extraction 
● Conducted quality assessment 
Dr Emma Rachel 
Rengasamy 
● Screened studies for eligibility 
● Extracted data 
● Checked data extraction 
● Assisted in writing results 
● Made supplementary table with complete list of studies 
Miss Lucretia 
Thomas  
● Screened studies for eligibility 
● Extracted data 
● Checked data extraction 
● Conducted quality assessment 
Dr Silviya 
Ralovska 
● Extracted Data 
● Checked data extraction 
● Conducted quality assessment 
Ms Abigail 
Smakowski 
● Checked data extraction 
● Conducted quality assessment 
● Supervised quality assessment 
● Arbitrated quality assessment 
Miss Ritika Dilip 
Sundaram 
● Extracted data 
● Checked data extraction 
● Conducted quality assessment 
Ms Camille 
Kaitlyn Hunt 
● Checked data extraction 
● Conducted quality assessment 
Dr Mao Fong Lim ● Checked data extraction 
● Conducted quality assessment 
● Arranged funding statements 
Dr Daruj 
Aniwattanapong 
● Checked data extraction 
Ms Vanshika 
Singh 
● Conducted quality assessment 
● Drafted implications for clinicians 
Dr Zain Hussain ● Conducted quality assessment 
● Assisted with creating tables of results 
Miss Stuti 
Chakraborty  
● Conducted quality assessment 
Miss Ella Burchill ● Conducted quality assessment 
● Adapted to house style 
Katrin Jansen ● Supported with meta-analysis methods  
● Conducted some of the meta-analyses 
Prof Dr Heinz 
Holling 
● Supported with meta-analysis methods  
● Advised on meta-analysis 
Dr Dean Walton ● Conducted quality assessment 
● Provided senior review of manuscript 
Dr Thomas A 
Pollak 
● Conducted quality assessment 
● Provided senior review of manuscript 
Dr Mark Ellul ● Conducted quality assessment 
● Provided senior review of manuscript 
Dr Ivan Koychev ● Conducted quality assessment 
● Provided senior review of manuscript 
Professor Tom 
Solomon 
● Provided senior review of manuscript 
Dr Benedict 
Daniel Michael 
● Provided senior review of manuscript 
Dr Timothy R 
Nicholson 
● Conceived the study 
● Provided senior leadership and advice throughout 
● Conducted quality assessment 
● Provided senior review of manuscript 
Dr Alasdair G 
Rooney 
● Conceived the study 
● Led and coordinated early phases of study 
● Wrote manuscript 
● Screened studies 
● Consulted on screening studies 
● Checked data extraction 
● Conducted OCEBM ratings 
● Conducted quality assessment 
● Provided senior review of manuscript 
 
PRISMA 2009 Checklist 
 
Section/topic  # Checklist item  
Reported on 
page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   pg 1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review registration number.  
 pg 5 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.   pg 6 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
pg 6-7  
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
pg 7 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
pg 7 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
pg 7   




Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
pg 8 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
pg 8   
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
Supplementary 
Table 2 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  
pg 8 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  pg 8 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
pg 8-9 
PRISMA 2009 Checklist 
 
Page 1 of 2  
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
pg 8 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
pg 8-9 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions 
at each stage, ideally with a flow diagram.  
Figure 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 









Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 







Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  pg 11-12 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  pg 11 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  pg 12-13 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
pg 14 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
pg 15 
PRISMA 2009 Checklist 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  pg 15-18 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for 





Supplementary table 2: Comprehensive list of fields which were extracted from eligible 
studies  
(asterisk denotes variables for which outcome measures were collected)  
 
Data items Prevalences  Mechanistic data Analytical statistics  
Title of study  Headache  C-reactive protein  Results from statistical 
tests reported by a 
study  
CEBM Levels of 
Evidence  
Myalgia  D-dimer  
Date of date collection Asthenia  Antibodies  
Funding source Dizziness/ vertigo  Cytokines  
Country of origin Tinnitus   Creatine kinase  
Ethics statement Hearing impairment  Computed tomography   
Number of recruitment 
settings 
Ataxia Magnetic resonance 
imaging  
 






Number of infected 
participants  
Obsessions  Cerebrospinal fluid 
analysis 
 
Number of control 
participants 
Palsy  Post-mortem findings  








Speech/aphasia    





Method of COVID-19 
diagnosis  
Seizures    
Stage of COVID-19 
pathway 
Neuralgia    
Severity of COVID-19 Ophthalmoplegia    
COVID-19 outcome Visual defect   
 
Follow-up period  Fatigue*   
Time-point in relation to 
infection 




Impaired taste*   
Neuropsychiatric and 
other relevant  
comorbidities  
Cognitive impairment*   
Methodological 
limitations as noted by 
the authors  
Depression*   
temporal onset of 
neuropsych 
complication (in relation 
to COVID-19 disease) 
Anxiety*   









 Stroke    




 Central demyelinating 
disorders  
  
 Motor neuropathy    
 Migraine    
 Sleep disorder    
 Catatonia    
 Dementia    
 Mania    
 Functional neurological 
disorder  
  
 Psychosis    
 




 Myopathy    
 Movement disorder    
 
  
Supplementary Table 1:  Summary table of studies reporting neuropsychiatric outcomes of COVID-19 infected patients. 
 




 Mean Age 
(S.D.) 
Male (%)  Outcomes 
(1) 




78 58.4 (13) 33 (42.3%) 




et al. (2020) 
USA Mixed 
Case series 
242 68.7 (16.5) 150 
Headache 5 (2%), Weakness 2 (0.8%), Dizziness/Vertigo 79 (32.6%), 
Focal neurological deficit 30 (12.4%), Altered mental status 102 (42.1%), 
Acute haemorrhagic stroke 11 (4.5%), Nonspecific white matter 
microangiopathy 134 (55.4%), Chronic infarct 47 (19.4%), Acute or 
subacute ischemic infarct 13 (5.4%) 
(3) 








Germany Outpatient  
Cross-sectional 







79 61.6 (17.4) 48 
Impaired smell and taste 31 (39.2%), Impaired smell onset 25 (31.7%), 




France  Outpatient 
Case series 
347 37* (-) 113 Impaired smell onset 345 (99.4%), Impaired taste at onset 123 (35.4%) 
(7) 




210 71* (-) 101 




et al. (2020) 
Spain - 
Case series 
131 50.4 (-) 56 
Headache 51 (38.9%), Myalgia 61 (46.6%), Asthenia 76 (58%), Impaired 
smell onset 77 (58.8%), Impaired taste at onset 74 (56.5%) 
(9) 






47.4 (14.5) 68767 
Headache 485 (56.7%), Myalgia 527 (61.6%), Smell and/or taste 507 
(59.2%) 
(10) 
















Headache 4 (25%), Myalgia 4 (25%), Dizziness/Vertigo 3 (19%), Fatigue 8 
(50%), Impaired smell 3 (19%),  
(12) 
Alsofayan 
Y.M. et al. 
(2020) 
Saudi Arabia Mixed 
Cross-sectional 
1519 36 * (-) 825 








841 66.4 (15.0) 473 
Headache 119 (14.1%), Myalgia 145 (17.2%), Asthenia 425 (51%), 
Dizziness/Vertigo 51 (6.1%), Seizures 6 (0.7%), Ophthalmoplegia 1 
(0.1%), Impaired smell onset 41 (4.9%), Impaired taste at onset 52 (6.2%), 
Depression 44 (5.2%), Anxiety 68 (8.1%), Impaired consciousness 165 
(19.6%), Ischaemic stroke 11 (1.3%), Haemorrhagic stroke 3 (0.4%), 
Meningoencephalitis 1 (0.1%), Guillain-Barre syndrome and variants 1 
(0.1%), Sleep disorders 109 (13%), Psychosis 11 (1.3%), Myopathy 26 
(3.1%), Movement disorder 6 (0.7%)  
(14) 




172 37.8 (12.5) 84 
Headache 97 (56.4%), Myalgia 125 (72.7%), Anosmia and Dysgeusia 72 
(41.9%), Impaired smell onset 88 (51.2%), Impaired smell follow-up 68 












Headache 38 (69.1%), Myalgia 17 (30.9%), Asthenia 28 (56%), Impaired 
smell onset 55 (100%), Impaired smell follow-up 35 (63.6%), Impaired 
taste onset 46 (83.6%) 
(16) 




145 47.5 (14.6) 54.50% 
Headache 24 (16.6%), Myalgia 20 (13.8%), Dizziness/Vertigo 29 (20%), 
Hearing impairment 2 (1.4%). Fatigue 59 (40.7%), Anorexia 62 (42.8%), 
Hypoacusis 2 (1.4%) 
(17) 




203 54 * (IQR 41-68) 108 (53.2%) 
Headache 10 (4.9%), Dizziness/Vertigo 4 (2%), Myalgia or Arthralgia 54 
(26.6%), Fatigue 16 (7.9%), Anorexia 6 (3%) 
(18) 















34 (11) (Range 
18-88) 
218 (40.2) 
Headache 393 (72.5%), Myalgia 340 (62.7%), Total anosmia 78 (14.4%) 
Impaired smell onset 444 (81.9%), Impaired smell follow-up 183 (33.8%), 








139 44.5 (-) 57 
Headache 24 (17.3%), Myalgia 20 (14.4%), Asthenia 22 (15.8%), 
Ophthalmoplegia 13 (9.3%), Anosmia and Dysgeusia 20 (14.3%)  
(21) 








Paresis 1 (4%), Focal neurological deficit 1 (4%), Stupor and Reduced 








(hospital) = 61.9 
(12.8), Group B 
(home) = 44.7 
(12.1) 
Group A 
(hospital) = 204 
Group B (home) 
= 81  
Headache 198 (38.9%), Myalgia 256 (50.4%), Asthenia 352 (69.3%), 
Impaired smell onset 283 (71.8%), Impaired smell follow-up 29 (19.7%), 
Impaired taste onset 321 (63.1%), Impaired taste follow-up 35 (19.7%) 
(23) 
Kim et al. 
(2020) 
South Korea Inpatient 
Cohort 
2491 62* (25)  1326 
Myalgia 722 (29.1%), Fatigue 722 (29.1%), Encephalitis 151 (6.1%), 
Central demyelinating disorders 151 (6.1%)  
(24) 
Kim et al. 
(2020) 
South Korea Community 
Cross-sectional 
213 26 * (-) 66 
Headache 54 (25.3%), Myalgia 54 (25.3%), Dizziness/Vertigo 32 (15%), 







23 80.7 (8.4) 7 Dizziness/Vertigo 1 (4.4%), Fatigue 4 (17.4%) 
(26) 
Klopfenstei




114 - - Anosmia and Dysgeusia 46 (38%). Impaired smell onset 54 (47.4%) 
(27) 






















308 61.8 (14.9) 64 
Fatigue 33 (10.7%), Focal neurological deficit 45 (14.6%), Seizures 16 
(5.2%) , Visual defect 6 (19.5%), Impaired smell onset 28 (%), Impaired 
consciousness 89 (28.9%), Guillain-Barre syndrome and variants 3 (1%) 
(30) 
Chung et al. 
(2020) 
Hong Kong Inpatient (mild) 
Cross-sectional 
18 28 (19) 41 Anosmia and Dysgeusia 9 (52.9%), Impaired smell onset 12 (67%) 
(31) 




26 37.6 (-) 16 (61.5%) Headache 8 (30.8%), Myalgia 10 (38.5%),  
(32) 




81 54.2 (17.0) 41 (50.6%) 
Impaired smell onset 50 (61.7%), Impaired taste onset 22 (27.2%) 
(33) 
Annweiler 
et al. (2020) 
France Mixed 
Cross-sectional 
353 84.7 (7) 160 (45.3%) 
Impaired smell onset 7 (2%), Impaired taste onset 25 (7.1%), Altered 





Spain  Population 
Cross-sectional 
909 34.7 (-)  283 (31.1%) 
Myalgia 296 (32.5%), Smell and Taste 824 (90.7%), Impaired smell onset 








225 - - Myalgia 128 (56.8%), Smell and Taste 110 (48.9%), Fatigue 150 (66.7%)  
(36) 






260 - - 
Headache 76 (81.7%), Myalgia 75 (80.6%), Fatigue 81 (87.1%), Smell or 
Taste 3 (3.2%) 
(37) 
Gorzkowski 
et al. (2020) 
France  Mixed  
Cohort 
229 39.7 (13.7) 82 (35.8%) 
Smell or Taste 140 (61.1%), Impaired smell at onset 124 (54.2%), Impaired 
smell at follow-up 6 (2.6%), Impaired taste at onset 140 (61.1%) 
(38) 




32 44 (-)  12 (37.5%) Myalgia or Fatigue 13 (52%) 
(39) 





palliative care)  
Case series 
101 82 (IQR 72-89) 64 (63.3%) Seizures 1 (1%), Fatigue 9 (8.9%), Delirium 24 (23.8%) 
(40) 






304 44* (IQR 33-59)  182 (59.9%) 
Seizures 2 (0.7%), Anxiety 1 (0.3%), Shock 8 (2.60%), Other 
cerebrovascular accident 4 (1.3%) 
(41) 
Sayin et al. 
(2020) 
Turkey  Mixed  
Case-control 
64 38.6 (10.1) 48 (75%) 
Headache 18 (39.1%), Smell or Taste 46 (71.9%), Impaired smell onset 43 
(67.2%), Impaired taste onset 46 (71.9%) 
(42) 
Schmithause
n et al. 
(2020) 
Germany 

















Headache 2 (2.63%), Weakness 1 (3.,7%), Focal neurological deficit 10 
(13.2%), Impaired taste at onset 1 (1.32%), Altered mental status 26 
(34,2%), Other cerebrovascular accident 4 (14.8%) 
(44) 













India Inpatient  
Cohort 




et al. (2020) 
Spain Inpatient 
Case series 
1683 66.8 (-)  18 (1.1%) 
Ischaemic stroke 17 (1.0%), Haemorrhagic stroke 5 (0.3%), Other 




Italy  Inpatient 
Case series 












58 (45.3%)  
Headache 52 (40%), Myalgia 60 (47%), Weakness 61 (48%), Impaired 
smell onset 49 (38%), Impaired taste onset 42 (32%) 
(49) 
Hintschich 





41 37 (-)  12 (29.3%) 
Smell and Taste 18 (44%), Impaired smell onset 22 (54%), Impaired taste 






1942 50* (-) 773 (39.8%)  
Smell and Taste 825 (42.5%), Impaired smell onset 956 (49.2%), Impaired 










Impaired smell onset (complete anosmia) 93 (74%), Impaired taste 






45 56 (16.9) 25 (55.6%)  Headache 10 (22%), Impaired smell onset 38 (84.4%) 
(53) 
Boscolo-






202 56*(-)  99 (49%)  
Headache 80 (39.6%), Myalgia 85 (42%), Dizziness/vertigo 25 (12.3%), 
Smell or Taste 113 (55.9%), Fatigue. 130 (64.3%) 
(54) 




41 49 (-) 30 (73.2%) Headache 3 (8%), Myalgia or Fatigue 18 (44%) 
(55) 




336 43 (IQR 30-54) 182 (54.1%)  
Headache 39 (11.6%), Myalgia 39 (11.6%), Weakness OR Fatigue 83 
(24.7%), Impaired consciousness/delirium/encephalopathy 1 (0.3%) 
(56) 
Parra et al. 
(2020) 
Spain  Inpatient 
Case series 
10 54.1(10.7) 6 (60%)  Psychosis 10 (100%) 
(57) 




72 38 (-) 41(56.9%) 
Headache 56 (77.8%), Myalgia 51 (70.8%), Impaired smell onset 53 






73 - - Smell or Taste 37 (51%)  
(59) 








Italy  Inpatient 
Case series 
19 76.1 (8.8) 10 (52.6%) Ischaemic stroke 17 (89.5%), Haemorrhagic stroke 2 (10.5%)  
(61) 
Pastor et al. 
(2020) 
Spain  Inpatient 
Case-control 




et al. (2020) 
Spain  Mixed  
Cross-sectional 
846 56.8 (15.7) 446 (52.1%) 
Smell and Taste 399 (47.2%), Impaired smell onset 454 (53.7%), Impaired 
taste onset 442 (52.2%) 
(63) 




93 67* (/IQR 54-72)  51 (54.8%) Headache 14 (15.1%), Myalgia 20 (21.5%)  
(64) 




770 50.4 (13.1) 370 (48.0%) Depression 332 (43.1%)  
(65) 



















107 65.8 (11.9) 82 (76.6%) 
Headache 12 (17.4%), Myalgia 16 (23.2%), Dizziness/vertigo 6 (8.7%), 
Fatigue 47 (68.1%), Impaired smell onset 15 (21.7%), Impaired taste onset 










Headache 10 (59%), Myalgia 8 (47%), Impaired smell onset 5 (29%), 
Impaired taste onset 5 (29%), Impaired 
consciousness/delirium/encephalopathy 1 (6%) 
(69) 
McLoughlin 







Impaired consciousness/delirium/encephalopathy 31 (43.7%), Sleep 
disorders 16 (22.5%), Psychosis 5 (7%)  
(70) 








141 45.6 (-)  
 
83 







10 75.6 (9.6) 5 (50%) Ischaemic stroke 9 (90%), Haemorrhagic stroke 1 (10%) 
(72) 




494 40 /IQR 27-59)  266 (53.8%) Smell and Taste 39 (7.9%)  
(73) 
Brandstetter 





31 - 5 (16%)  Headache 15 (48.4%), Myalgia 15 (48.4%) Fatigue 13 (41.9%)  
(74) 
 Jäckel et al. 
(2020) 
Germany  Inpatient 
Case series 
20 65.5 (11.0) 16 (80%) Delirium 13 (65%) 
(75) 




92 52.9 (13.3) 62 (67.4%) 
Headache 20 (21.7%), Myalgia 57 (62%), Smell and Taste 15 (16.3%), 
Impaired smell onset 22 (23.9%), Impaired smell follow-up 1 (1%)  
(76) 




159 (70% under 39) 50 (31.4%) 
Smell and Headache 116 (73%), Impaired smell onset 159 (100%), 
Impaired smell follow-up 88 (55.3%), Impaired taste onset 147 (92.5%) 
(77) 








31  - - Impaired smell onset 7 (22.6%)  
(78) 
Kandemirli 













239  46.5 (15.4) 133 (55.7%) 
Headache 64 (26.7%), Myalgia 36 (15.1%), Dizziness/vertigo 16 (6.7%), 
Tinnitus 5 (2.1%), Hearing impairment 3 (1.3%), Visual defect 8 (3.3%), 
Smell and Taste 11 (4.6%), Impaired smell onset 18 (7.5%), Impaired taste 
onset 16 (6.7%), Impaired consciousness/delirium/encephalopathy 23 
(9.6%), Ischaemic stroke 7 (2.9%), Haemorrhagic stroke 2 (0.8%), 









64 (47.8%)  
Headache 87 (64.9%), Myalgia 76. (56.7%), Asthenia 104 (77.6%), 
Dizziness/vertigo 27 (20.1%) Visual defect 6 (4.5%), Smell and/or Taste 
87 (64.9%), Impaired smell onset 69 (51.5%), Impaired taste onset 85 
(63.4%) 
(81) 




from ITU 1 
month ago 
Cross-sectional 
100 65 (15) 39 (39%) 
Smell and Taste 28 (28%), Impaired smell onset 29 (29%), Impaired smell 
follow-up 5 (5%), Impaired taste onset 41 (41%), Impaired taste follow-up 
7 (7%) 
(82) 
Menni et al. 
(2) (2020) 
UK / USA App users  
Cohort 
7178 41.6(-)  (-)  
Smell and Taste 4668 (65%), Fatigue 2093(29.2%), Impaired 









79 9.5 (IQR 3–15) 48 (60.8%)  





Italy  Mixed  
Cross-sectional 
204 52.6 (14.4) 110 (53.9%) 
Headache 32 (15.7%), Myalgia 20 (9.9%), Dizziness/vertigo 43 (21.1%), 
Fatigue 46 (22.6%), Impaired smell onset 85 (41.7%), Impaired taste onset 
113 (55.4%)  
(85) 




114 44.6 (16.1) 52 (45.60%) 
PHQ-2 and GAD-2 scores increased significantly from baseline (adjusted 
incidence rate ratio 1.40 [1.10 - 1.78], p=0.006) 
(86) 
Speth et al. 
(2) (2020) 
Switzerland  Mixed 
Cross-sectional 






37 61 (12) 30 (81.0%) 
Headache 4 (11%), Focal neurological deficit 4 (11%), Seizures 5 (14%), 
Impaired consciousness/delirium/encephalopathy 27 (73%), Haemorrhagic 
stroke 11 (29.7%), Other cerebrovascular accident 9 (24%), Sleep disorders 
15 (41%), Post ICU neuropsychiatric abnormality 15 (41%)  
(88) 





head CT  
Cross-sectional 
63 77.8 (17.8)  39 (61.9%) Olfactory cleft opacification 16 (25%) 
(89) 
Sun et al. 
(2020) 
China  Mixed  
Case series 
55 44 (IQR 34-56) 31 (56.4%) Headache 6 (10.9%), Myalgia 10 (18.2%), Dizziness/Vertigo 6 (10.9%) 
(90) 







22 59.5 (16) 10 (45.4%)  Ischaemic stroke 19 (86.4%), Haemorrhagic stroke 3 (13.6%) 
(91) 
Chary et al. 
(2020) 
France Mixed   
Cohort 
115 47 (-) 34 (29.6%)  
Headache 62 (54%), Myalgia 57 (50%), Smell and Taste 38 (33%), 
Impaired smell onset 81 (70%), Impaired smell follow-up 29 (25.2%)  
(92) 
Lapostolle 
et al. (2020) 







 IQR 32-57 (M) 
IQR 30-54 (F)  
700 (47.7%) 
Headache 803 (55.3%), Myalgia 823 (6.7%), Asthenia 864 (59.5%), 








78 40.6 (11.2) 32  (41.0%)  Impaired smell onset 78 (100%), Impaired taste onset 53 (67.9%) 
(94) 
Lechien et 









Europe Mixed  
Cross-sectional 







1420 39.2 (12.1) 458 (32.3%) 
Headache 998 (70.3%), Myalgia 887 (62.5%), Asthenia 514 (36 %), Smell 
and Taste 875 (61.6%), Impaired smell onset 997 (70.2%), Impaired smell 




al. (5)  
(2020) 
Europe Mixed  
Cross-sectional 
2013 39.5 (12.1) 684 (34.0%) 
Headache 1411 (70.1%), Myalgia 1244 (61.8%), Impaired smell onset 
1751 (87%), Impaired smell follow-up 282 (14%), Impaired taste onset 





Belgium Outpatient  
Cross-sectional 
86 41.7 (11.8) 30 (34.9%)  
Headache 42 (60%), Myalgia 30 (42.9%), Asthenia 51 (72.9 %), 
Speech/aphasia 17 (24.3%), Visual defects 18 (25.7%), Fatigue 51 (73%), 
Impaired smell onset 86 (100%), Impaired taste onset 44 (51%) 
(99) 




22 46.3 (11.1) 20 (90.9%) Ischaemic stroke 22 (100%) 
(100) 







31 64.9 (15.7) 68  Stroke 31 (100%) 
(101) 




56 38 (/IQR 32–53)  23 (41.10%) 
Headache 10 (17.9%), Smell and Taste 20 (35.7%), Fatigue 4 (7.1%), 
Impaired smell onset 31 (55.4%), Impaired taste onset 32 (57.1%) 
(102) 






61 - - 
Dysfunctional coronavirus anxiety associated with coronavirus infection 
(OR 3.04 [1.28-7.25]) 
(103) 
Lee et al. (3) 
(2020) 
Korea Inpatients  
Case series 
98 72* (IQR 68-79) 44 (44.9%) Focal neurological deficit 7 (9%) 
(104) 
Lee et al. (4) 
(2020) 





1,161 (36.4%) Smell and Taste 488 (15.3%) 
(105) 
Li et al. 
(2020) 
China Inpatient   
Case series 






1916 64* (IQR 51-76) 1101 (57.5%) Ischaemic stroke 31 (1.6%) 
(107) 




60 46.6 (12.2) 40 (66.7%)  
Headache 22 (37%), Myalgia 5 (8%),Tinnitus 1 (2%), Smell OR Taste 21 
(35%), Impaired smell onset 59 (96.3%) , Impaired taste onset 4 (7%),  
(108) 






- - - 
Most frequently reported neurological findings: headache (61.9%), myalgia 
(50.4%), anosmia (49.2%), ageusia (39.8), impaired consciousness 
(29.3%), psychomotor agitation (26.7%), encephalopathy (21.0%), acute 






40,469 - 18,364 (45.4%)  
Headache 150 (3.7%), Myalgia 821 (2%), Dizziness/vertigo 379 (0.9%), 
Focal neurological deficit 392 (1%), Seizures 258 (0.6%), Smell and Taste 
477 (1.2%), Depression 1549 (3.8%), Anxiety 1869 (4.6%), Impaired 
consciousness/delirium/encephalopathy 937 (2.3%), Other cerebrovascular 
accident 406 (1.%), Sleep disorders 1394 (3.4%), Other movement 
disorders 277 (0.7%), Suicidal ideation 63(0.2%)  
(110) 




280 104 (51-65) 135 (48.2%) 
Fatigue 172 (61.4%), Depression 114 (40.7%), Anxiety 174 (62.1%), Sleep 
disorders 178 (63.6%) 
(111) 




93 51 (17.5)  41 (44.1%)  Myalgia 34 (37%), Fatigue 63 (68%) 
(112) 






































Encephalopathy 10 (23%), inflammatory CNS syndromes 12 (28%), 
ischaemic stroke 8 (19%), peripheral neurological disorders 8 (19%), 
miscellaneous CNS disorders 5 (12%) 
(114) 
D'Ascanio 
et al. (2020) 
Italy Mixed 
Case-control 









and those they 
lived with  
Cross-sectional 
42  
31* (Range <1 - 
>90) 
69 (-) 
Headache 32 (76%), Myalgia 24 (57%), Light-headed 3 (7%), Smell OR 
Taste 16 (38%), Fatigue 15 (36%), Impaired smell onset 18 (43%), 










Fatigue 143 (40.3%), Impaired smell onset 237 (66.8%) , Impaired smell 
follow-up 88 (24.8%), Impaired taste onset 232 (65.4%), Impaired taste 
follow-up 84 (36.2%)  
(117) 




104 68*(IQR 47-75) 54 (51.9%) - 
(118) 
Tian et al. 
(2020) 
China  Inpatient 
Case series 








90 - 19 (21.1%) 
Headache 64 (71.1%), Myalgia 57 (63.3%), Impaired smell onset 37 
(46.8%) 
(120) 
Du et al. 
(2020) 





7 (58.3%) Headache 3 (25%), Fatigue 10 (83%) 
(121) 
Du W et al 
(2020) 
China  Inpatient 
Case series 




Australia  Outpatient 
Cross-sectional 
28 55* (IQR 46-64) 14 (50%)  
Headache 6 (21.4%), Myalgia 15 (53.6%), Smell and Taste 3 (10.7%), 
Impaired smell onset 7(25%) 
(123) 
















10 50* (-) 7 (70%) Headache 10 (100%), Fatigue 10 (100%)  
(126) 




50 37.7 (17.9) 30 (60.0%) 
Headache 24 (48%), Myalgia 18 (36%), Asthenia 25 (50%), Impaired 
smell onset 46 (92%), Impaired smell follow-up 9 (18%), Impaired taste 
onset 35 (70%), Impaired taste follow-up 4 (8%) 
(127) 
Galanopoul




22 63.2 (11.9) 14 (63.6%) 
Seizures 14 (63.6%), Impaired consciousness/delirium/encephalopathy 15 
(68.2%)  
(128) 




198 45*(IQR 28) 284 (143.0%) 
Smell and Taste 58 (29.3%), Impaired smell onset 82 (41.4%), Impaired 
taste onset 92 (46.5%)  
(129) 
Vacchiano 







Headache 46 (43%), Myalgia 37 (34%), Dizziness/vertigo 11 (10%), 
Impaired smell onset 40 (37%), Impaired taste onset 66 (61%) 
(130) 
Vaira et al. 
(2020) 
Italy Mixed   
Cross-sectional 
345 48.5 (12.8) 146 (42.3%) Impaired smell onset 241(70%), Impaired taste onset 155 (44.9%) 
(131) 
Vaira et al.  
(2020) 
Italy  Inpatient 
Cross-sectional 
72 49.2 (13.7) 27 (37.5%) 
Headache 30 (41.6%), Asthenia 48 (66.7%), Smell and Taste 30 (41.7%), 
Impaired smell onset 14 (14.4%), Impaired taste onset 9 (12.5%), Impaired 
taste follow-up 9 (12.5%)  
(132) 
Boscolo-




54 - - Smell or Taste 34 (63%)  
(133) 
Burke et al. 
(2020) 
USA Mixed   
Case series 
164 50 (-) 92 (56%) 










18 - 11 (61.1%) Seizures 0 (0%) 
(135) 




12 14.5 (IQR 9--16) 6 (50.0%) Dizziness/vertigo 2 (16.7%), Fatigue 1 (8.3%)  
(136) 




113 68 (IQR 62-77) 83 (73.5%) 
Headache 11 (10%), Myalgia 21 (19%), Dizziness/vertigo 10 (9%), Fatigue 
64 (57%), Impaired consciousness/delirium/encephalopathy 25 (22%)  
(137) 





39.1, 37*, (IQR 
15-99) 
-  Asthenia  1,154363 (46.6%), Smell or Taste 325,910 (17.1%) 
(138) 




25 52 (19.3) 15 (60.0%)  Fatigue 14 (56%) 
(139) 






92 61*(IQR 55-70)  73 (79.3%) Ischaemic stroke 2 (2.2%), Haemorrhagic stroke 2 (2.2%)  
(140) 
Gaborieau 





– 10)  
94 (59.9%) Smell or Taste 7 (4.5%) 
(141) 
Garrazzino 
et al. (2020) 
Italy Mixed   
Case series 
168 5 (IQR 0.3-9.6)  94 (56.0%) Seizures 3 (1.8%), Fatigue 3 (1.8%) 
(142) 




103 42.5 (12.5) 59 (57.3%) Depression 62 (60.2%), Anxiety 59 (55.3%), PTSD 1 (10%)  
(143) 




237 39.6 (14.6) 108 (45.6%) 
Headache 88 (37%), Impaired smell onset 173 (73%), Impaired smell 
follow-up 65 (27%) 
(144) 




655 - 367 (56.0%) Headache 80 (12.2%), Myalgia 78 (11.9%), Fatigue 184 (28.1%) 
(145) 








Headache 12 (14%), Myalgia 8 (9.3%), Tinnitus 3 (3.5%), Smell and Taste 
and Tinnitus 44 (51.2%), Fatigue 16 (18.6%), Impaired smell onset 34 
(39.5%), Impaired taste onset 33 (38.4%)  
(146) 






321 -  151 (47%) 
Headache 34 (10.6%), Myalgia 14 (12.5%), Dizziness/vertigo 6 (1.9%), 
Smell or Taste 42 (13.1%), Fatigue 52 (16%), Ophthalmic symptoms 6 
(1.9%) 
(147) 





43.6 (M) (2.7) 
50.0 (F) (1.8)  
32 (53.3%) 
Headache 8 (12.7%), Dizziness/vertigo 12 (20%), Fatigue 23 (38%), 
Impaired taste onset 8 (12.7%) 
(148) 




214 52.7 (15.5) 87 (40.7%) 
Headache 28 (13.1%), Dizziness/vertigo 36 (16.8%), Ataxia 1 (0.5%), 
Seizures 1 (0.5%), Neuralgia 5 (2.3%), Visual defects 3 (1.4%), Impaired 
smell onset 11 (5.1%), Impaired taste onset 12 (5.6%), Impaired 
consciousness 16 (7.5%), Other cerebrovascular accident 6 (2.8%), 









38 (57.6%  
Impaired consciousness/delirium/encephalopathy 11 (16.7%), New 
confusion 11 (16.7%)  
(150) 
Naeini et al. 
(2020) 
Iran Mixed  
Cross-sectional 
49 45.1 (12.2) 27 (55.1%) 
Headache 35 (71.4%), Fatigue 31 (63%), Impaired smell onset 49 (100%), 




Vietnam  Outpatient 
Cross-sectional 
1387 - - 
Participants with COVID-19 more likely to have depression (OR 2.88, 
p<0.001) and lower average HRQOL (p<0.001) 
(152) 






10 61.3 (-) 5 (50.0%) 
Cerebral Performance Category <2 (poor outcome): 5 (50%); 3-5 (good 
outcome): 5 (50%) 
(153) 




306 38.3 (11.0) 149 (48.7%) 










36 69.1 (-) 26 (72.2%) 
Confusion or fluctuating alertness 23 (58%), delayed awakening after 








300 43.6 (12.2) 75 (25.0%) 
Headache 133 (44.3%), Myalgia 128 (42.7%), Asthenia 109 (36.3%), 
Smell and Taste 164 (54.7%), Impaired smell onset 26 (8.7%), Impaired 











Headache 15 (6.7%), Myalgia 71 (31.6%), Dizziness/vertigo 8 (3.6%), 
Fatigue 34 (15.1%), Impaired smell onset 31 (13.8%), Impaired 
consciousness/delirium/encephalopathy 15 (6.7%) 
(157) 




50 59.6 (-) 29 (58.0%) 
Headache 12 (24%), Ataxia 1 (2%), Palsy 3 (6%), Paraesthesia 1 (2%), 
Seizures 13 (26%), Hypogeusia and Dysgeusia 5 (10%), Impaired smell 
onset 3 (6%), Altered mental status 30 (60%), Ischaemic stroke 10 (20%) , 
Haemorrhagic stroke 4 (8%), SAH 4 (8%), TIA 1 (2%), Hypoxic ischemic 
brain injury 7 (14%), Meningoencephalitis 2 (4%), Myopathy 6 (12%), 








103 74 (IQR 50-90)  63 (61.2%) 
Seizures 3 (2.9%), Ischaemic stroke 3 (2.9%), Haemorrhagic stroke 8 











112 43.4 (11.4) 21 (18.8%) 
Headache 112 (100%), Photophobia 32 (28.6%), Impaired smell onset 11 
(9.8%) 
(160) 




1875 63 (IQR 51-70)  945 (50.4%) 
Headache 123 (6.6%) , Myalgia 259 (13.8%), Dizziness/vertigo 87 (4.6%), 
Fatigue 477 (25.4%), Impaired consciousness/delirium/encephalopathy 16 
(0.9%), Phonophonbia 46 (41.1%), Allodynia 5 (4.5%), Autonomic 
Symptoms 22 (19.6%) 
(161) 







161 38.8 (IQR 23-53) 92 (57.1%) 
Smell and Taste 93 (24%), Impaired smell onset 61 (15%), Impaired taste 
onset 7 (2%) 
(162) 
Radmanesh 






9 (81.8%) Impaired consciousness/delirium/encephalopathy 11 (100%) 
(163) 




12 56.3  6 (50.0%) Ischaemic stroke 10 (83.3%), Haemorrhagic stroke 2 (16.7%) 
(164) 






161 59.4 (16.6) 104 (64.6%) Headache 5 (3.1%), Fatigue and Myalgia 17 (10.6%) 
(165) 














202 56 (IQR 45-67)  97 (48.0%) 
Headache 86 (42.6%),  Myalgia 90 (44.6%), Smell or Taste 130 (64.4%), 
Fatigue 138 (68.3%) 
(167) 









8 (57.1%) Fatigue 3 (21.4%) 
(168) 
Sun et al. 
(2020) 















USA Mixed  
Cross-sectional 
350 43* (IQR 32-57)  165 (47.1%) 
Headache 171 (60%)  Myalgia 167 (58%), Smell and/or Taste 163 (56%), 
Fatigue 198 (69%), Impaired smell onset 140 (49%), Impaired taste onset 
143 (50%), Confusion 41 (14%) 
(170) 






33 51.8 (-) 11 (33.3%) 
Smell and Taste 13 (39.4%), Impaired smell onset 17 (51.5%), Impaired 
taste onset 17 (51.5%) 
(171) 
Varatharaj 







Focal neurological deficit 1 (0.8%), Seizures 1 (0.8%), Cognitive 
impairment 6 (4.8%), Depression 3 (2.4%), Impaired 
consciousness/delirium/encephalopathy 9 (7.2%), Ischaemic stroke 57 
(45.65), Haemorrhagic stroke 9 (7.2%), Other cerebrovascular accident 11 
(8.8%), Meningoencephalitis 7 (5.6%), Guillain-Barre syndrome 4 (3.2%), 












10 48 (-) 3 (30.0%) 
Headache 3 (30%), Weakness 4 (40%), Impaired smell onset 8 (80%), 
Impaired taste onset 9 (90%), Polyarthralgia 2 (20%) 
(173) 
Vespignani 












Seizures 1 (20%), Impaired smell onset 1 (20%) 
(174) 
Wang et al. 
(2020) 





59 (45%)  Dizziness/vertigo 2 (1.5%), Fatigue 10 (7.6%) 
(175) 
Wu et al. 
(2020) 
France Inpatient  
Cross-sectional 
14 - 7 (50.0%)  Fatigue 8 (57.1%), Anxiety 13 (92.9%) 
(176) 




66 - 34 (51.5%) 
Headache 11 (16.7%) Myalgia 16 (24.2%), Fatigue 26 (39.3%), Ischaemic 
stroke 5 (3.3%) 
(177) 




21 54 (15.4) 13 (61.9%) Myalgia 1 (4.8%), Weakness 4 (19%) 
(178) 
Xiong et al. 
(2020) 
China Inpatient  
Cohort 
917 48.7 (17.1) 504 (55.0%) 
Headache 2 (0.2%), Myalgia 2 (0.2%), Syncope 3 (0.3%), Neuralgia 1 
(0.1%), Delirium 7 (0.8%), Other cerebrovascular accident 10 (1.1%)  
(179) 
Yan et al. 
(2020) 
USA Mixed   
Cross-sectional 
59 - 29 (49.2%) 
Headache 39 (66.1%), Myalgia 37 (62.7%), Fatigue 48 (81.4%), Impaired 
smell onset 13 (22%), Impaired smell follow-up 40 (67.8%), Impaired taste 
onset 12 (20.3%), Impaired taste follow-up 42 (71.2%) 
(180) 
Yan et al. 
(2)  (2020) 
USA Mixed  
Cross-sectional 
316 - - Impaired smell onset 23 (7.3%), Impaired smell follow-up 18 (23%) 
(181) 




136 56 (/IQR 44-64)  66 (48.5%) Dizziness/vertigo 12 (8.8%), Fatigue 53 (39%), Sleep disorders 49 (36%)  
(182) 
Yin et al. 
(2020) 
China Mixed   
Cohort 
30 52.7 (15.1) 19 (63.3%) Headache 5 (16.7%), Myalgia 4 (13.3%), Fatigue 8 (26.7%) 
(183) 




1859 59 (IQR 45-68)  934 (50.2%) Headache 107 (6%), Myalgia 315 (17%), Fatigue 695 (37%) 
(184) 




129 64 (/IQR 56-69)  56 (43.4%) Myalgia 25 (19.4%), Fatigue 39 (30.2%) 
(185) 
















32 (39.0%) Depression 3 (3.7%), Anxiety 5 (6.1%), Sleep disorder 24 (29.3%) 
(187) 
Zayet et al. 
(2020) 






Headache 51 (72.9%), Myalgia 41 (58.6%), Tinnitus 7 (10%), Hearing loss 
4 (5.7%), Blurred vision 3 (4.3%), Fatigue 65 (92.9%), Impaired smell 
onset 37 (52.9%), Impaired taste onset 34 (48.6%) 
(188) 








Headache 74 (77.7%), Myalgia 71 (74.7%), Smell and/or Taste 70 (73.7%), 
Impaired smell onset 60 (63.2%), Impaired taste onset 62 (65.3%) 
(189) 
Zhang et al. 
(92020) 
China Mixed   
Cohort 
221 55*(IQR 39-67) 108 (48.9%) Headache 17 (7.7%), Fatigue 156 (70.6%) 
(190) 







108 (55.7%) Headache 33 (17.0%), Myalgia 44 (22.7%) 
(191) 




869 51* (IQR 40-58)  377 (43.4%) 
Headache 18 (2.1%), Myalgia 114 (13.1%), Dizziness/vertigo 12 (1.4%), 
Fatigue 226 (26%) 
(192) 




29 56 (IQR 32 -66)  14 (48.3%) Headache 3 (10.3%), Myalgia 3 (10.3%), Fatigue 8 (27.6%) 
(193) 




19 48*(IQR 27-56)  11 (57.9%) Headache 2 (10.5%), Fatigue 2 (10.5%)  
(194) 







80 (49.7%) Headache 12 (7.5%), Myalgia 18 (11.2%), Fatigue 64 (39.8%) 
(195) 




34 66*(IQR 58-76)  23 (67.6%) Headache 2 (5.9%), Myalgia 5 (14.7%), Fatigue 2 (5.9%) 
(196) 




29 47 (10.5) 18 (62.1%) 
No significant differences between total scores on Trail Making Test, Sign 
Coding Test, Continuous Performance Test and Digital Span Test among 
recovered COVID-19 patients compared to healthy controls. 
(197) 




21 66.1 (13.9) 13 (61.9%) Myalgia 2 (9.5%), Fatigue 5 (23.8%) 
(198) 
Mahammedi 







Headache 13 (12%), Myalgia 13 (12%), Ataxia 2 (2%), Seizures 10 (9%), 
Neuralgia 3 (3%), Impaired smell onset 2 (2%), Impaired 
consciousness/delirium/encephalopathy 64 (59%), Ischaemic stroke 34 
(31%), Haemorrhagic stroke 6 (5.6%), Guillain-Barre syndrome 2 (20%), 
















Headache 20 (48%), Myalgia 24 (57%), Dizziness/vertigo 9 (21%), Fatigue 
29 (69%), Impaired smell onset 15 (36%), Impaired smell follow-up 4 









11 31(Range 18-39) 0 (0.0%) PHQ-9 and GAD-7 scores highest at time of institution of lockdown rules 
(202) 






69.3) (in events) 
23 (71.9%) (in 
events) 
Stroke 32 (0.9%) 
(203) 
Yan et al. 
(2020) 






Headache 62 (48.4%), Fatigue 90 (70.3%), Impaired smell onset 75 
(58.6%), Impaired taste onset 70 (54.7%) 
(204) 







127 (48.5%) Headache 17 (6.5%), Fatigue 69 (26.3%) 
(205) 






58 63*(-) -  
Focal neurological deficit 39 (67%), Cognitive impairment 14 (36%), 






463 57.5 (16.8) 204 (44.1%) Headache 74 (16%), Myalgia 194 (42%)  
(207) 







43 (65.2%) Myalgia 36 (55%), Fatigue 44 (67%) 
(208) 
Dogra et al.  
(2020) 






Speech/aphasia 1 (3%), Focal neurological deficit 7 (21.2%), Seizures 2 
(6.1%), Impaired consciousness/delirium/encephalopathy 17 (51.1%), 
Haemorrhagic stroke 31 (93.9%), Other cerebrovascular accident 11 






417 36.9 (11.4) 154 (36.9%) 
Headache 188(45%), Myalgia 242 (58%), Asthenia 188 (45%), Impaired 
smell onset 284 (79.6%), Impaired taste onset 342 (88.8%) 
(210) 




4039 41.4 (12.2) 1118 (27.7%) 
Mean reductions in smell (-79.7±28.7), taste (-69.0±32.6) and chemesthetic 
function (-37.3±36.2) during COVID-19 
(211) 










103 55 (14.7) 59 (57.3%) 
Headache 40 (38.3%), Myalgia 25 (24.7%), Dizziness/vertigo 27 (26.2%), 
Hearing impairment 2 (1.9%), Paraesthesia 6 (5.8%), Fatigue 33 (32%), 
Impaired smell onset 40 (38.3%), Impaired taste onset 48 (46.6%), 
Depression 39 (37.9%), Anxiety 34 (33%), Impaired 
consciousness/delirium/encephalopathy 23 (22.2%), Sleep disorders 51 
(49.5%) 
(213) 




154 - - Smell or Taste 35 (22.7%) 
(214) 
Giacomelli 
et al. (2020) 
Italy  Inpatient 
Cross-sectional 
59 60* (IQR 50-74)  40 (67.8%) 
Headache 2 (3.4%), Asthenia 1 (1.7%), Smell and Taste 11 (28.9%), 










Headache 16 (22%) , Myalgia 13 (18%), Weakness 29 (40%), Impaired 
smell onset 26 (36.1%), Impaired taste onset 42 (58.3%)  
Outcomes refer to all COVID-19 infected patients. Mean age given, where median age used, illustrated by *, IQR/Range specified.  
HCW = Health Care Workers. ICH = intracranial haemorrhage. ICU = Intensive Care Unit. MRI = Magnetic resonance imaging. ED = Emergency Department. CT = Computed tomography. CT Angiogram = Computed tomography 
angiography. SAH = Subarachnoid haemorrhage. TIA = Transient ischaemic attack. CNS = Central Nervous System.  
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Supplementary Table 4: Comparison of proportion estimation models 
 
 GLMM Double-arcsine transformation 
Symptom/Syndrome Prevalence (%) 95% CI I2  Prevalence (%) 95% CI I2  
Headache 20.7 16.1 - 26.1 99.0% 24.3 19.6 - 29.4 99.2% 
Myalgia 25.1 19.8-31.3 99.1% 28.6 23.5 - 33.9 99.3% 
Anosmia 43.1 35.2 – 51.3 98.8% 45.0 37.8 - 51.5 98.6% 
Fatigue 35.7 29.2 – 42.9 98.4% 37.1 30.9 - 43.5 98.4% 
Dysgeusia  37.2 29.8 – 45.3  98.6% 39.5 32.8 - 46.5 98.5% 
 
Supplementary table 5: Subgroup analysis by country of origin 
Outcome  Country (N studies) Prevalence % 95% CI p 
Headache (84 studies) China (32) 7.8 5.7-10.4 (reference) 
Italy (12) 28.0 19.4-38.6 <0.001 
USA (12) 32.6 18.4-51.0 <0.001 
Myalgia (76 studies) China (27) 10.4 7.1-15.1 (reference) 
USA (13) 34.0 19.1-52.9 0.001 
Italy (10) 26.4 18.7-35.9 <0.001 
Fatigue (67 studies) China (30) 31.2 24.5-38.8 (reference) 
Italy (11) 31.1 18.9-46.8 1.00 
USA (11) 64.2 56.7-70.9 <0.001 
Anosmia (63 studies) Italy (15) 41.1 26.7-57.1 (reference) 
France (9)  35.5 18.4-57.4 0.67 
USA (8) 27.2 12.1-50.5 0.31 
Dysgeusia (52 studies) Italy (13) 39.1 26.0-54.1 (reference) 
France (6) 39.1 21.3-60.4 1.00 
USA (6) 45.0 27.8-63.4 0.63 
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